Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer

被引:7
|
作者
Noh, Joseph J. [1 ]
Kim, Myeong-Seon [2 ]
Cho, Young-Jae [3 ]
Jeong, Soo-Young [1 ]
Lee, Yoo-Young [1 ]
Ryu, Ji-Yoon [3 ]
Choi, Jung-Joo [3 ]
Bae, Illju [4 ]
Wu, Zhaoyan [4 ]
Kim, Byoung-Gie [1 ]
Hwang, Jae Ryoung [3 ]
Lee, Jeong-Won [1 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol,Sch Med, Seoul 06351, South Korea
[2] Catholic Univ Korea, Dept Obstet & Gynecol, St Vincents Hosp, Seoul 16247, South Korea
[3] Sungkyunkwan Univ, Samsung Med Ctr, Res Inst Future Med, Sch Med, Seoul 06351, South Korea
[4] Chemas Co Ltd, Seoul 06163, South Korea
基金
新加坡国家研究基金会;
关键词
cervical cancer; tetraarsenic hexoxide; patient-derived xenograft; autophagy; cisplatin; ARSENIC TRIOXIDE; TETRAARSENIC OXIDE; GROWTH-INHIBITION; OVARIAN-CANCER; PROLIFERATION; CARCINOMA; APOPTOSIS; SYNERGISM; CELLS;
D O I
10.3390/pharmaceutics12100987
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the anti-cancer effects of tetraarsenic hexoxide (TAO, As4O6) in cervical cancer cell lines and in a series of patient-derived xenograft (PDX) mouse models. Methods: Human cervical cancer cell lines, including HeLa, SiHa and CaSki, and human umbilical vein endothelial cells (HUVECs), were used to evaluate the anti-cancer activity of TAO. Cellular proliferation, apoptosis, and enzyme-linked immunosorbent assay (ELISA) for matrix metallopeptidase 2 (MMP-2) and 9 (MMP-9) were assessed. The tumor weights of the PDXs that were given TAO were measured. The PDXs included primary squamous cell carcinoma, primary adenocarcinoma, recurrent squamous cell carcinoma, and recurrent adenocarcinoma. Results: TAO significantly decreased cellular proliferation and increased apoptosis in cervical cancer cell lines and HUVEC. The functional studies on the cytotoxicity of TAO revealed that it inhibited the activation of Akt and vascular endothelial growth factor receptor 2 (VEGFR2). It also decreased the concentrations of MMP-2 in both cervical cancer cell lines and HUVECs. Active caspase-3 and p62 were both increased by the treatment of TAO, indicating increased rates of apoptosis and decreased rates of autophagy, respectively. In vivo studies with PDXs revealed that TAO significantly decreased tumor weight for both primary squamous cell carcinoma and adenocarcinoma of the cervix. However, this anti-cancer effect was not seen in PDXs with recurrent cancers. Nevertheless, the combination of TAO with cisplatin significantly decreased tumor weight in PDX models for both primary and recurrent cancers. Conclusions: TAO exerted inhibitory effects on angiogenesis, cellular migration, and autophagy, and it showed stimulatory effects on apoptosis. Overall, it demonstrated anti-cancer effects in animal models for human cervical cancer.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [41] Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types
    Moskovits, Neta
    Peretz, Idit
    Chausky, Eva
    Itzhaki, Ella
    Shmuel, Nofar
    Meerson, Raisa
    Tarasenko, Nataly
    Kaufman, Aleksandr
    Stemmer, Amos
    Yaffe, Ranny
    Bareket-Samish, Avital
    Edison, Natalia
    Goldman, Tal
    Stemmer, Salomon M.
    CANCER LETTERS, 2022, 536
  • [42] Murine Endogenous Retroviruses Are Detectable in Patient-Derived Xenografts but Not in Patient-Individual Cell Lines of Human Colorectal Cancer
    Bock, Stephanie
    Mullins, Christina S.
    Klar, Ernst
    Perot, Philippe
    Maletzki, Claudia
    Linnebacher, Michael
    FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [43] The novel tubulin-binding 'tumor checkpoint controller' BAL101553 has anti-cancer activity alone and in combination treatments across a panel of GBM patient-derived xenografts
    Mladek, Ann C.
    Pokorny, Jenny L.
    Lane, Heidi
    Bachmann, Felix
    Schroeder, Mark A.
    Bakken, Katrina K.
    Carlson, Brett L.
    Decker, Paul A.
    Eckel-Passow, Jeanette E.
    Sarkaria, Jann N.
    CANCER RESEARCH, 2016, 76
  • [44] Patient-derived xenografts (PDX) identify JMJD6 inhibitor as an effective therapeutic medicine in colorectal cancer
    Ye, F.
    You, J.
    Xia, L.
    Lian, J.
    Xiao, R.
    Ran, T.
    Gao, X.
    Li, J.
    Zhao, X.
    Gao, J.
    Lin, H.
    Zheng, J.
    Liu, W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
    Hasegawa, K.
    Yagishita, S.
    Shintani, D.
    Yoshida, H.
    Suzuki, M.
    Sato, S.
    Ogasawara, A.
    Nishikawa, T.
    Yonemori, K.
    Yasuda, M.
    Furuuchi, K.
    Uenaka, T.
    Hamada, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S529 - S529
  • [46] Novel Second-Generation Rexinoid Reduces Cancer Cell Stemness in Human Neuroblastoma Patient-Derived Xenografts
    Marayati, Raoud
    Williams, Adele P.
    Bownes, Laura V.
    Quinn, Colin H.
    Atigadda, Venkatram R.
    Stewart, Jerry E.
    Aye, Jamie M.
    Yoon, Karina J.
    Beierle, Elizabeth A.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 231 (04) : S207 - S208
  • [47] A comparative study of tumour-on-chip models with patient-derived xenografts for predicting chemotherapy efficacy in colorectal cancer patients
    Ong, Louis Jun Ye
    Chia, Shumei
    Wong, Stephen Qi Rong
    Zhang, Xiaoqian
    Chua, Huiwen
    Loo, Jia Min
    Chua, Wei Yong
    Chua, Clarinda
    Tan, Emile
    Hentze, Hannes
    Tan, Iain Beehuat
    DasGupta, Ramanuj
    Toh, Yi-Chin
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2022, 10
  • [48] Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification
    Ren, Yongxin
    Zheng, Jianming
    Fan, Shiming
    Wang, Linfang
    Cheng, Min
    Shi, Dongxia
    Zhang, Wei
    Tang, Renxiang
    Yu, Ying
    Jiao, Longxian
    Ni, Jun
    Yang, Haibin
    Cai, Huaqing
    Yin, Fang
    Chen, Yunxin
    Zhou, Feng
    Zhang, Weihan
    Qing, Weiguo
    Su, Weiguo
    ONCOTARGET, 2017, 8 (31) : 50832 - 50844
  • [49] Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies
    Odunsi, Adekunle
    McGray, A. J. Robert
    Miliotto, Anthony
    Zhang, Yali
    Wang, Jianming
    Abiola, Adebukola
    Eppolito, Cheryl
    Huang, Ruea-Yea
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [50] Establishment of Human Patient-Derived Endometrial Cancer Xenografts in NOD scid Gamma Mice for the Study of Invasion and Metastasis
    Unno, Kenji
    Ono, Masanori
    Winder, Abigail D.
    Maniar, Kruti P.
    Paintal, Ajit S.
    Yu, Yanni
    Wei, Jian-Jun
    Lurain, John R.
    Kim, J. Julie
    PLOS ONE, 2014, 9 (12):